This week in industry includes trials on elenbecestat to be discontinued, ofatumumab demonstrating superiority to Aubagio and the Toca 5 trial results failing to meet primary endpoint.
Browsing: Clinical trials
In this written ‘Ask the Experts’ column, we bring together leaders from our partnered organizations (Alzheimer’s Research UK, Alzheimer’s Society and the UK DRI) to discuss what the future of dementia research might hold.
Ponesimod hits key endpoints in clinical trial for relapsing multiple sclerosis: industry news round-up
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
Whilst at the AD/PD™ conference, we had the pleasure of speaking with Patrik Brundin about his talk on novel therapeutic targets for Parkinson’s disease.
Biogen and Eisai have announced the decision to discontinue the global Phase III trials of aducanumab for Alzheimer’s disease.
Two clinical trials of a combined therapy targeting the opioid system have suggested significant symptom reduction in people with major depression.
Scientists have discovered a vicious feedback loop underlying brain degeneration in Alzheimer’s, which may explain why many drug trials have failed.
Research presented at AAIC reveals the development of the National Strategy and how community based outreach increases participation in Alzheimer’s research.
A potential new therapeutic for inherited amyotrophic lateral sclerosis, which extended survival and reversed fatal neuromuscular damage in rodents, has entered Phase I/II clinical trials.
An independent data monitoring committee has advised that lanabecestat is unlikely to meet primary endpoints, leading to the decision to discontinue trials.